PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics

Pharmacogenet Genomics. 2019 Aug;29(6):136-154. doi: 10.1097/FPC.0000000000000376.

Authors

Tyler Stevens¹, Katrin Sangkuhl², Jacob T Brown³, Russ B Altman^{2

4

5

6}, Teri E Klein^{2

6}

Affiliations

¹ College of Pharmacy.
² Departments of Biomedical Data Sciences.
³ Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota.
⁴ Biomedical Engineering.
⁵ Genetics.
⁶ Medicine, Stanford University, Stanford, California, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Attention Deficit Disorder with Hyperactivity / drug therapy*
Attention Deficit Disorder with Hyperactivity / genetics
Carboxylic Ester Hydrolases / genetics
Dopamine Plasma Membrane Transport Proteins / genetics
Humans
Methylphenidate / pharmacokinetics*
Norepinephrine Plasma Membrane Transport Proteins / genetics
Pharmacogenetics / methods*
Pharmacogenomic Variants

Substances

Dopamine Plasma Membrane Transport Proteins
Norepinephrine Plasma Membrane Transport Proteins
SLC6A2 protein, human
SLC6A3 protein, human
Methylphenidate
Carboxylic Ester Hydrolases
CES1 protein, human

Grants and funding